A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. - Fox E; Lovett-Racke AE; Gormley M; Liu Y; Petracca M; Cocozza S; Shubin R; Wray S; Weiss MS; Bosco JA; Power SA; Mok K; et al. (Multiple sclerosis (Houndmills, Basingstoke, England), 2021)